Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 55

1.

Understanding resistance to combination chemotherapy.

Pritchard JR, Lauffenburger DA, Hemann MT.

Drug Resist Updat. 2012 Oct;15(5-6):249-57. doi: 10.1016/j.drup.2012.10.003. Epub 2012 Nov 17. Review.

PMID:
23164555
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Non-Hodgkin's B-cell lymphoma: advances in molecular strategies targeting drug resistance.

Maxwell SA, Mousavi-Fard S.

Exp Biol Med (Maywood). 2013 Sep;238(9):971-90. doi: 10.1177/1535370213498985. Epub 2013 Aug 28. Review.

PMID:
23986223
[PubMed - indexed for MEDLINE]
3.

Nanoparticle-based combination therapy toward overcoming drug resistance in cancer.

Hu CM, Zhang L.

Biochem Pharmacol. 2012 Apr 15;83(8):1104-11. doi: 10.1016/j.bcp.2012.01.008. Epub 2012 Jan 18. Review.

PMID:
22285912
[PubMed - indexed for MEDLINE]
4.

Targeted therapies for gastric cancer: current status.

Yoong J, Michael M, Leong T.

Drugs. 2011 Jul 30;71(11):1367-84. doi: 10.2165/11592530-000000000-00000. Review.

PMID:
21812503
[PubMed - indexed for MEDLINE]
5.

Overview of resistance to systemic therapy in patients with breast cancer.

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.

Adv Exp Med Biol. 2007;608:1-22. Review.

PMID:
17993229
[PubMed - indexed for MEDLINE]
6.

Molecular mechanisms of drug resistance.

Longley DB, Johnston PG.

J Pathol. 2005 Jan;205(2):275-92. Review.

PMID:
15641020
[PubMed - indexed for MEDLINE]
7.

Understanding resistance to targeted cancer drugs through loss of function genetic screens.

Berns K, Bernards R.

Drug Resist Updat. 2012 Oct;15(5-6):268-75. doi: 10.1016/j.drup.2012.10.002. Epub 2012 Nov 9. Review.

PMID:
23142522
[PubMed - indexed for MEDLINE]
8.

Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy.

Abdollahi A, Folkman J.

Drug Resist Updat. 2010 Feb-Apr;13(1-2):16-28. doi: 10.1016/j.drup.2009.12.001. Epub 2010 Jan 12. Review.

PMID:
20061178
[PubMed - indexed for MEDLINE]
9.

A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments.

Masui K, Gini B, Wykosky J, Zanca C, Mischel PS, Furnari FB, Cavenee WK.

Carcinogenesis. 2013 Apr;34(4):725-38. doi: 10.1093/carcin/bgt086. Epub 2013 Mar 1. Review.

PMID:
23455378
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Molecularly targeted therapeutics for breast cancer.

Hussain SA, Palmer DH, Spooner D, Rea DW.

BioDrugs. 2007;21(4):215-24. Review.

PMID:
17628119
[PubMed - indexed for MEDLINE]
11.

Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies.

Tortora G, Bianco R, Daniele G, Ciardiello F, McCubrey JA, Ricciardi MR, Ciuffreda L, Cognetti F, Tafuri A, Milella M.

Drug Resist Updat. 2007 Jun;10(3):81-100. Epub 2007 May 7. Review.

PMID:
17482503
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Endocrine therapy and other targeted therapies for metastatic breast cancer.

Hussain SA, Palmer DH, Moon S, Rea DW.

Expert Rev Anticancer Ther. 2004 Dec;4(6):1179-95. Review.

PMID:
15606341
[PubMed - indexed for MEDLINE]
13.

Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib.

Broxterman HJ, Gotink KJ, Verheul HM.

Drug Resist Updat. 2009 Aug-Oct;12(4-5):114-26. doi: 10.1016/j.drup.2009.07.001. Epub 2009 Aug 3. Review.

PMID:
19648052
[PubMed - indexed for MEDLINE]
14.

Mechanisms of drug resistance in chemotherapy for urogenital carcinoma.

Naito S, Yokomizo A, Koga H.

Int J Urol. 1999 Sep;6(9):427-39. Review.

PMID:
10510888
[PubMed - indexed for MEDLINE]
15.

Review of the contemporary cytotoxic and biologic combinations available for the treatment of metastatic breast cancer.

Tkaczuk KH.

Clin Ther. 2009;31 Pt 2:2273-89. doi: 10.1016/j.clinthera.2009.11.011. Review.

PMID:
20110041
[PubMed - indexed for MEDLINE]
16.

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.

Plosker GL, Figgitt DP.

Drugs. 2003;63(8):803-43. Review.

PMID:
12662126
[PubMed - indexed for MEDLINE]
17.

Adjuvant breast cancer therapy: current status and future strategies--growth kinetics and the improved drug therapy of breast cancer.

Norton L.

Semin Oncol. 1999 Feb;26(1 Suppl 3):1-4. Review.

PMID:
10203263
[PubMed - indexed for MEDLINE]
18.
19.

Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal.

Tsuruo T, Naito M, Tomida A, Fujita N, Mashima T, Sakamoto H, Haga N.

Cancer Sci. 2003 Jan;94(1):15-21. Review.

PMID:
12708468
[PubMed - indexed for MEDLINE]
20.

A review of mechanisms of circumvention and modulation of chemotherapeutic drug resistance.

O'Connor R.

Curr Cancer Drug Targets. 2009 May;9(3):273-80. Review.

PMID:
19442048
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk